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Summary 24 
For many viruses, endocytosis and exposure to the low pH within acidic 25 
endosomes is essential for infection. It has previously been reported that FCV uses 26 
clathrin-mediated endocytosis for entry into mammalian cells. Here we report that 27 
infection of RAW264.7 macrophages, by the closely related murine norovirus-1, does not 28 
require the clathrin pathway, as infection was not inhibited by expression of dominant-29 
negative Eps15 or by knock down of the AP-2 complex. Further, infection was not 30 
inhibited by reagents that raise endosomal pH.  RAW264.7 macrophages were shown not 31 
to express caveolin, and flotillin depletion did not inhibit infection, suggesting that 32 
caveolae and the flotillin pathway are not required for cell-entry. However, MNV-1 33 
infection was inhibited by methyl-β-cyclodextrin and the dynamin inhibitor, dynasore. 34 
Addition of these drugs to the cells after a period of virus internalisation did not inhibit 35 
infection, suggesting the involvement of cholesterol sensitive lipid-rafts and dynamin in 36 
the entry mechanism. Macropinocytosis was shown to be active in RAW264.7 37 
macrophages (as indicated by uptake of dextran) and could be blocked by EIPA, which is 38 
reported to inhibit this pathway. However, infection was enhanced in the presence of 39 
EIPA. Similarly, actin disruption, which also inhibits macropinocytosis, resulted in 40 
enhanced infection.  These results suggest that macropinocytosis could contribute to virus 41 
degradation or that inhibition of macropinocytosis could lead to the up-regulation of other 42 
endocytic pathways of virus uptake.   43 
 44 
 45 
 46 
Introduction  47 
The Caliciviridae are divided into four genera; Vesivirus, Lagovirus, Sapovirus 48 
and Norovirus. The human noroviruses are the most common cause of acute viral 49 
gastroenteritis, especially in industrialised countries (Lopman et al., 2003); there is 50 
currently no treatment or vaccine for these viruses. In addition, there is still no routine 51 
tissue culture system for the propagation of human noroviruses, but the recent discovery 52 
of murine norovirus-1 (MNV-1) has provided an efficient model system for the study of 53 
norovirus replication, as this virus replicates efficiently in murine macrophages and 54 
dendritic cells (DCs) (Karst et al., 2003; Wobus et al., 2004). MNV-1 is highly prevalent 55 
in laboratory mice and has been shown to be lethal to mice with impaired innate 56 
immunity (Hsu et al., 2006; Karst et al., 2003; Muller et al., 2007).   57 
Noroviruses are non-enveloped and contain a single- stranded RNA genome of 58 
about 7.3 kb, which is linked to the viral VPg protein at the 5’ end and is polyadenylated 59 
at the 3’ end (Karst et al., 2003; Wobus et al., 2004). The genome is organised into 4 60 
open-reading frames (ORF1-4). ORF-1 encodes the non-structural proteins whereas 61 
ORF-2 and ORF-3 encode structural proteins (Sosnovtsev et al., 2006).  ORF-4 was 62 
recently identified within the MNV-1 genome and encodes a single protein of unknown 63 
function (Thackray et al., 2007).   64 
For many viruses, infection requires virus uptake by endocytosis. A number of 65 
different endocytic pathways have been identified in mammalian cells. Broadly, these are 66 
divided into clathrin-mediated endocytosis  and clathrin-independent endocytosis (CIDE) 67 
pathways which  include caveolin-dependent endocytosis (or caveolae-mediated 68 
endocytosis) and a number of caveolin-independent pathways such as macropinocytosis, 69 
and the flotillin-dependent and CLIC/GEEC (clathrin-independent cargos/GPI-AP-70 
enriched early endosomal compartment) pathways (Glebov et al., 2006; Marsh & 71 
Helenius, 2006; Miaczynska & Stenmark, 2008). CIDE pathways show different 72 
requirements for cellular proteins such as dynamin, flotillin and small GTPases (Glebov 73 
et al., 2006; Marsh & Helenius, 2006; Miaczynska & Stenmark, 2008).  Although each 74 
endocytic pathway was originally thought of as being distinct, it is now clear that they 75 
can overlap considerably and vesicles derived from CIDE can fuse with vesicles derived 76 
from the clathrin-dependent pathway (Doherty & McMahon, 2009). 77 
Viruses can exploit CME and CIDE for entry into cells (Marsh & Helenius, 2006). 78 
Further, a number of viruses have been shown to utilize more than one pathway for 79 
internalization. For  example, influenza virus has been shown to utilize both CME  and a 80 
CIDE pathway for infection (Rust et al., 2004) and SV40 can use  at least two distinct 81 
lipid raft-mediated endocytic pathways for uptake (Damm et al., 2005; Pelkmans et al., 82 
2001; Pelkmans et al., 2002).   83 
Currently, little is known of the mechanisms used by noroviruses to bind and 84 
enter cells. Recently, it was shown that feline calicivirus (FCV) uses junctional adhesion 85 
molecule A (JAM-A) as an attachment receptor (Makino et al., 2006). In addition, FCV 86 
has been shown to bind to 2,6-sialic acid (Stuart & Brown, 2007), which could serve as a 87 
co-receptor for infection. Also, FCV is known to be internalised  by CME as infection is 88 
inhibited by expression of  dominant-negative mutants of proteins (Eps15 and Rab5) that 89 
are normally involved in clathrin-mediated endocytosis (Stuart & Brown, 2006).   90 
MNV-1 replicates efficiently in macrophages and dendritic cells (Wobus et al., 91 
2004) and recently sialic acid was identified as a cellular receptor for MNV-1 on the 92 
mouse macrophage cell line, RAW264.7 cells (Taube et al., 2009).  However, in contrast 93 
to FCV, a recent report (Perry et al., 2009) showed that MNV-1 infection of RAW264.7 94 
cells and primary DCs is pH-independent, suggesting that the entry pathway is clathrin 95 
independent. Here, we have investigated the cell entry mechanism used by MNV-1 to 96 
infect RAW264.7 cells. Our results suggest that MNV-1 entry can occur via a pathway 97 
that is clathrin- and caveolae-independent but requires dynamin and cholesterol.  98 
 99 
Results 100 
 101 
MNV-1 infection of RAW 264.7 cells is clathrin-independent 102 
As FCV is closely related to MNV-1 and has been shown to utilize CME for entry 103 
into cultured cells, we determined if MNV-1 also utilizes this same pathway to infect 104 
RAW264.7 cells. Eps15 is a molecular scaffold protein which associates with both the 105 
AP-2 adaptor protein complex (Benmerah et al., 1996; Benmerah et al., 1995; Iannolo et 106 
al., 1997) and epsin 1 (Chen et al., 1998), and is required for CME of transferrin. 107 
RAW264.7 cells were transfected to express a dominant-negative (DN) form of Eps15 108 
that is known to inhibit clathrin-mediated endocytosis (DN-Eps15 E∆95/295; (Benmerah 109 
et al., 1999), or a control form of Eps15 (DIII∆2) that lacks one of the AP-2 binding sites  110 
and does not interfere with the clathrin pathway.  The transfected cells were identified by 111 
confocal microscopy via an eGFP tag on the Eps15 proteins (shown in green in Figure 1). 112 
At 12 h post-transfection, the cells were infected with MNV-1 at a low multiplicity of 113 
infection (MOI ~ 2), to favour virus uptake via the most efficient entry pathway. After 12 114 
h, the cells were fixed and labelled using antisera to the viral NS7 polymerase protein to 115 
identify infected cells. The Eps15-expressing cells (green) were scored for infection (red) 116 
and the number of infected cells in the DN-Eps15 expressing cell population normalised 117 
to the level of infection of the cells expressing the control protein (DIII∆2). This showed 118 
that expression of the DN Eps15 did not appear to inhibit MNV-1 infection (Figure 1A) 119 
suggesting that CME is not the entry route used by MNV-1 to infect RAW264.7 cells. To 120 
confirm that expression of DN-Eps15 inhibited CME, transfected RAW264.7 cells were 121 
also incubated with Alexa-labelled transferring, a commonly used marker for CME 122 
(Hinrichsen et al., 2003). As expected, expression of the control Eps15 DIII∆2 protein 123 
had no effect on transferrin (red) uptake, whereas cells expressing the dominant negative 124 
Eps15 showed reduced transferrin uptake (Figure 1B and 1C).  125 
To confirm that CME is not required for MNV-1 infection, RAW264.7 cells were 126 
transfected with siRNA targeted to the AP-2 adaptor complex. AP-2 is one of the major 127 
components of clathrin coat assembly and plays a central role in formation of clathrin 128 
coated pits (Mills, 2007). Following transfection, immunoblotting was performed to 129 
confirm a knock-down of AP-2 (Figure 1E). Transfection with AP-2 siRNA also 130 
inhibited transferrin uptake, confirming that CME was inhibited (Figure 1D and 1G). 131 
siRNA-transfected cells were also infected with MNV-1 and infection scored by confocal 132 
microscopy, as described above. Although AP-2 levels were greatly reduced and CME 133 
was inhibited, knockdown of AP-2 expression had no effect on MNV-1 infection (Figure 134 
1F).  Taken together, these results strongly suggest that MNV-1 does not use CME as the 135 
major entry route of RAW 264.7 cells. 136 
 137 
Inhibition of endosomal acidification does not affect MNV-1 infection 138 
A recent study has suggested that MNV-1 infection does not require endosome 139 
acidification (Perry et al., 2009). To confirm this, we investigated the effect of 140 
concanamycin A on MNV-1 infection. Concanamycin A is a potent and specific inhibitor 141 
of the vacuolar proton ATPase (Huss et al., 2002) and is commonly used to raise the pH 142 
within endosomes. RAW264.7 cells were treated with concanamycin A (or with DMSO 143 
as control) for 0.5 h prior to MNV-1 infection for 1 h. The cells were washed and 144 
incubated for a further 11 h, and infection quantified using the ELISPOT assay (Figure 145 
2A) (Berryman et al., 2005).  Treatment of cells with concanamycin-A had no effect on 146 
MNV-1 infection (Figure 2B), confirming that MNV-1 infection does not require virus 147 
exposure to the low pH within acidic endosomes.  148 
 149 
Depletion of cellular cholesterol inhibits MNV-1 endocytosis 150 
Cholesterol depletion affects a number of endocytic pathways, including caveolin-151 
dependent endocytosis (Pelkmans et al., 2001; Smith et al., 2003), as well as other lipid-152 
raft mediated pathways ((Damm et al., 2005; Vidricaire & Tremblay, 2007). MβCD 153 
depletes cholesterol from the plasma membrane and disrupts lipid rafts and endocytic 154 
pathways that involve these structures. RAW264.7 cells were pre-treated with MβCD (or 155 
DMSO) for 0.5 h and then infected with MNV-1 in the presence, or absence (no drug 156 
control) of the drug for 1 h. The virus inoculum and drug were removed by washing and 157 
infection continued at 37 0C for a further 11 h, before quantification using the ELISPOT 158 
assay. Treatment of cells with MβCD decreased MNV-1 infection by approximately 50% 159 
(Figure 3A). To confirm that the drug affected only an early step in infection, and not 160 
subsequent virus replication, the drug was also added immediately after, or 1.5 h after the 161 
virus inoculum was removed. Under these conditions, no effect on infection was 162 
observed (Figure 3A), indicating that MβCD inhibited only the cell entry process and not 163 
subsequent steps in the replication cycle.  164 
To ensure that MβCD did not inactivate the virus itself, virus was incubated with 165 
MβCD or DMSO (control) and residual infectivity measured by TCID50. This analysis 166 
showed that MβCD treatment had no effect on MNV-1 infectivity for RAW264.7 cells 167 
(data not shown). Addition of soluble cholesterol to RAW264.7 cells after MβCD 168 
treatment reversed the inhibitory effect of MβCD on infection (Figure 3C), further 169 
suggesting cholesterol is required for MNV-1 entry. 170 
 To confirm that MβCD treatment resulted in inhibition of lipid raft-dependent 171 
endocytosis, we analysed the effect of the drug on cholera toxin B (CTB) uptake. CTB is 172 
internalised in a lipid raft-dependent manner after binding to its receptor GM1 173 
ganglioside (Fujinaga et al., 2003). CTB internalisation was blocked when RAW264.7 174 
cells were treated with MβCD, confirming that lipid raft-dependent endocytosis was 175 
inhibited (Figure 3B). Furthermore, as severe cholesterol depletion has been shown to 176 
also inhibit CME (Vela et al., 2007), we confirmed that MβCD treatment did not inhibit 177 
uptake of Alexa-568 transferrin (data not shown). These data suggest that MNV-1 178 
infection is cholesterol-sensitive and likely to be mediated by a lipid-raft dependent 179 
pathway. 180 
 181 
Caveolin-1 is not expressed in RAW 264.7 cells 182 
The above results show that MNV-1 infection is sensitive to cholesterol depletion 183 
and may therefore be mediated via lipid-rafts. Caveolae-mediated endocytosis is initiated 184 
at lipid rafts and inhibited by cholesterol depletion. Therefore, we investigated the role of  185 
caveolae in MNV-1 infection. Caveolae formation requires the caveolin (Morrow & 186 
Parton, 2005), however a number of reports have shown that RAW264.7 cells lack 187 
caveolin and therefore caveolae (Cameron et al., 1997; Fra et al., 1994; Gorodinsky & 188 
Harris, 1995; Lyden et al., 2002).  In order to confirm the absence of caveolin-1 in our 189 
RAW264.7 cells, we subjected RAW264.7 cell lysates to immunoblotting. Figure 3D 190 
shows that caveolin was detected in HEK293 cells but not in RAW 264.7 cells (Figure 191 
3D). This is entirely consistent with previous reports that RAW264.7 cells lack this 192 
protein. Thus, the MNV-1 entry pathway in RAW264.7 cells is not dependent on 193 
caveolae. 194 
 195 
MNV-1 endocytosis is dynamin-dependent  196 
Dynamin-2 is a GTPase that mediates vesicle fission from the plasma membrane 197 
and is required for both clathrin- and caveolae-mediated endocytosis (Damke et al., 1994; 198 
Henley et al., 1998; Oh et al., 1998). To assess if dynamin is involved in MNV-1 199 
infection, we used dynasore, a small-molecule inhibitor of dynamin (Macia et al., 2006). 200 
RAW264.7 cells were treated with dynasore (or DMSO) for 0.5 h, prior to MNV-1 201 
infection.  The virus inoculum was removed and the cells were incubated at 370C for a 202 
further 11 h in the presence, or absence (control) of dynasore (as the effects of dynasore 203 
are rapidly reversible). The cells were then fixed and infection quantified using the 204 
ELISPOT assay.  Treatment of RAW264.7 cells with dynasore inhibited infection by 205 
85% (Figure 4A). Addition of the drug immediately after, or 1.5 h after the virus 206 
inoculum was removed, had no effect on infection, suggesting that the drug only affected 207 
entry and not a subsequent intracellular replication step. We also confirmed that dynasore 208 
did not inactivate virus in solution using the same approach as described for MβCD 209 
above (data not shown). As the drug remained present throughout the entire assay, we 210 
also assessed any cytotoxic effects on the cells. This analysis showed that only ~5% of 211 
cells displayed signs of cytotoxicity after 12 h treatment with dynasore (data not shown). 212 
In order to confirm that dynasore inhibited dynamin-dependent endocytosis, we analyzed 213 
the effect of the drug on uptake of Alexa-labelled transferrin. As expected, transferrin 214 
uptake was inhibited by dynasore (data not shown). These results suggest that dynamin is 215 
required for MNV-1 infection of RAW264.7 cells. 216 
 217 
Microtubules are involved in MNV-1 infection 218 
Nocodazole interferes with microtubule function and vesicular trafficking through 219 
the endosomal pathway (D'Hondt et al., 2000). RAW264.7 cells were treated with 220 
nocodazole (or DMSO) for 0.5 h prior to MNV-1 infection and infection was quantified 221 
using the ELISPOT assay.  Nocodazole treatment inhibited MNV-1 infection by 40-50 % 222 
(Figure 4B), suggesting that an early stage of MNV-1 infection requires intact 223 
microtubules. Addition of the drug immediately after the virus inoculum was removed 224 
also had a small inhibitory effect on infection, suggesting that microtubules may also be 225 
involved in trafficking of the virus post-entry.  At the concentrations used, nocodazole 226 
was shown to disrupt the microtubules, as revealed by indirect immunofluorescence 227 
confocal microscopy using anti-tubulin antisera (data not shown). 228 
 229 
Blocking macropinocytosis enhances MNV-1 infection 230 
Macropinocytosis (MPC) is used by a number of viruses for infectious entry 231 
(Mercer & Helenius, 2008). To determine if MPC is active in RAW264.7 cells, we used 232 
uptake of Alexa-labelled dextran (Dharmawardhane et al., 2000). Figure 5B shows that 233 
dextran was internalised by RAW264.7 cells, indicating that MPC was active.  Next, we 234 
investigated the effect of EIPA on infection. EIPA is an analogue of amiloride and  235 
inhibits Na+/H+ exchangers and MPC without affecting other endocytic pathways such as 236 
CME, or cavoelae-mediated endocytosis (West et al., 1989). We first confirmed that 237 
EIPA blocked MPC in RAW264.7 cells by showing that treatment of the cells with this 238 
drug inhibited dextran uptake (Figure 5B). However, we found that EIPA had an 239 
unexpected effect on MNV-1 infection, as treatment of cells with EIPA resulted in 240 
enhanced MNV-1 infection (by 47% at 25 µM and 67% at 50 µM) (Figure 5A).  Actin 241 
filaments are important for MPC, therefore we investigated the effect of actin disruption 242 
on MNV-1 infection using cytochalasin-D, which prevents actin polymerization and 243 
disrupts the actin cytoskeleton (Brenner & Korn, 1980). Consistent with the effect of 244 
EIPA, cytochalasin-D treatment of RAW264.7 cells also enhanced MNV-1 infection 245 
(Figure 5C) by about 60%. At the concentrations used, cytochalasin D was shown to 246 
disrupt actin filaments, as revealed by indirect immunofluorescence confocal microscopy 247 
using Alexa-conjugated phalloidin (Figure 5D). 248 
 249 
Depletion of flotillin-1 does not inhibit MNV-1 internalisation 250 
We also analysed the effect of flotillin-1 depletion on MNV-1 infection. Flotillin-251 
1 is associated with lipid rafts and was recently identified as a component of a novel 252 
CIDE pathway (Glebov et al., 2006; Lang et al., 1998; Volonte et al., 1999). RAW264.7 253 
cells were transfected with siRNA against flotillin-1 and inhibition of flotillin-1 254 
expression confirmed by immunoblotting (Figure 6A); no effect on flotillin-1 expression 255 
was observed when compared to cells transfected with a control siRNA targeted to GFP. 256 
This knock-down of flotillin-1 had no effect on MNV-1 infection (Figure 6B), 257 
suggesting that the flotillin-1-dependent pathway is not involved in MNV-1 entry. 258 
 259 
Discussion 260 
Viruses have been shown to utilize a number of different endocytic pathways to 261 
enter and infect cells. CME would appear to be the most commonly used but it is 262 
increasingly clear that a number of CIDE pathways are also used by several different 263 
viruses.  It has recently been shown that entry of MNV-1 into RAW264.7 cells is pH-264 
independent (Perry et al., 2009). In this study we have further examined the entry route 265 
used by MNV-1 to infect RAW264.7 cells. Initially, we investigated if infection by 266 
MNV-1 is dependent on CME, since FCV (which is closely related to MNV-1) is 267 
internalised via this pathway (Stuart & Brown, 2006). Our experiments show that 268 
dominant negative Eps-15 and AP-2 knock-down inhibited transferrin uptake but had no 269 
effect on MNV-1 infection, strongly suggesting that the mechanism of MNV-1 entry is 270 
clathrin-independent. Similarly, concanamycin A treatment confirmed that a low pH 271 
within endosomes is not required for MNV-1 infection, further supporting the conclusion 272 
that a clathrin-independent pathway is most likely required for MNV-1 entry.  273 
A number of CIDE pathways originate from lipid rafts. These pathways require 274 
cholesterol and can be inhibited by the cholesterol-depleting agent MβCD. We found that 275 
treatment of RAW264.7 cells with MβCD inhibited MNV-1 infection, but only when the 276 
drug was added during virus entry and not when added after virus uptake. Repletion of 277 
cholesterol after MβCD treatment restored infection, further suggesting that cholesterol is 278 
required for MNV-1 infection.   279 
Our data suggests that MNV-1 entry into RAW264.7 cells is cholesterol and 280 
hence lipid raft-dependent. Caveolae-dependent endocytosis also requires intact lipid-281 
rafts and hence, is normally inhibited by cholesterol depletion (Murata et al., 1995). 282 
Caveolin is a key component of caveolae (Morrow & Parton, 2005); however, a number 283 
of previous studies have shown that RAW264.7 cells lack caveolin (Cameron et al., 284 
1997; Fra et al., 1994; Gorodinsky & Harris, 1995; Lyden et al., 2002). and we have 285 
confirmed these observations in our RAW264.7 cells. These data do not rule out the 286 
possibility that MNV-1 infection may occur through a caveolae-dependent pathway in 287 
other cell types which express caveolin.  The recently described flotillin-dependent 288 
pathway is also raft-associated (Glebov et al., 2006) and may be inhibited by cholesterol 289 
depletion; however, our results showed that flotillin-1 depletion had no effect on MNV-1 290 
infection, suggesting that this pathway is also not used for MNV-1 infection.   291 
The role of dynamin in both CME and caveolae-dependent endocytosis is well-292 
established, whereas its role in other endocytic pathways is less clear (Marsh & Helenius, 293 
2006; Miaczynska & Stenmark, 2008). Here we show that inhibition of dynamin using 294 
dynasore decreased MNV-1 infection of RAW264.7 cells, but only when added at the 295 
entry stage of infection, indicating that MNV-1 entry is dynamin-dependent.   296 
Treatment of RAW.264.7 cells with nocodazole (which disrupts microtubules) 297 
also inhibited MNV-1 infection.  However, at this stage we cannot be certain if  298 
microtubules are required for entry or post-entry virus trafficking as the drug also 299 
inhibited infection when added immediately after the virus inoculum was removed and 300 
further studies are required to understand the precise role for microtubules during virus 301 
entry.  302 
Recently, a number of viruses have been shown to use MPC, or MPC-like entry 303 
pathways for infection (reviewed in Mercer and Helenius, 2009). MPC is especially 304 
active in specialised antigen-presenting cells, such as macrophages and dendritic cells. 305 
Therefore, we also investigated a role for MPC in MNV-1 infection. We established that 306 
MPC was active in RAW264.7 cells but surprisingly, inhibition of MPC, by either EIPA 307 
or cytochalasin D, resulted in an increase in MNV-1 infection. At present we do not know 308 
why inhibiting MPC should lead to an increase in infection.  A possible explanation is 309 
that MPC is responsible for a large proportion of fluid-phase uptake and inhibition of 310 
MPC could result in up-regulation of other endocytic pathways (by way of compensation) 311 
that could then be used for MNV-1 uptake. Alternatively, it is possible that a proportion 312 
of virus enters RAW264.7 cells by MPC and is delivered to lysosomes for destruction. If 313 
this is the case then inhibition of MPC may lead to enhanced infection.  However, further 314 
studies are needed to understand this phenomenon. 315 
In conclusion, we have presented evidence that infection of RAW264.7 cells by 316 
MNV-1 is mediated by a clathrin-, caveolae-, flotillin- and pH-independent pathway that 317 
requires intact lipid-rafts, dynamin and microtubules. Together these studies suggest that 318 
different members of the calicivirus family may utilize different cell entry pathways for 319 
infection.  320 
 321 
Methods 322 
 323 
Cell culture and viruses  324 
RAW264.7 and HEK293 cells were cultivated in Dulbecco’s modified Eagle’s 325 
medium (DMEM) and modified Eagle’s medium (MEM), respectively, supplemented 326 
with 10% foetal bovine serum, non-essential amino acids (1 %), penicillin (100 U/ml) 327 
and streptomycin (100 mg/ml; Gibco-BRL) at 37 °C with 5% CO2. MNV-1 (strain CW.1) 328 
was the gift of Prof. Herbert Virgin (Washington University, St. Louis, MO) and was 329 
propagated in RAW264.7 cells. The virus titre was determined by TCID50 on RAW264.7 330 
cells. 331 
 332 
Antibodies and reagents 333 
The anti-α-tubulin antisera (DM1A) was from Sigma. Anti-flotillin-1 antisera 334 
(clone 18) was from BD Biosciences. Anti-adaptin-2 (AP-2) monoclonal antibody (sc-335 
55497) and polyclonal anti-caveolin-1 sera (sc-894) were from Santa Cruz Biotechnology. 336 
The anti-GAPDH monoclonal antibody (6C5) was from Ambion. The anti-MNV NS7 337 
polymerase polyclonal sera was a gift of Dr Ian Goodfellow (Imperial College, London, 338 
UK). Alexa-568 transferrin, alexa-555 cholera toxin B and alexa-555 dextran were all 339 
from Invitrogen, as were the Alexa-Fluor-conjugated secondary antibodies. 5-(N-Ethyl-340 
N-isopropyl) amiloride (EIPA), concanamycin A, cytochalasin D, nocodazole, dynasore, 341 
and methyl-β-cyclodextrin (MβCD) and water soluble cholesterol (C4951) were from 342 
Sigma. Stock solutions of concanamycin A, EIPA, cytochalasin D, dynasore and 343 
nococodazole were prepared in dimethyl sulfoxide (DMSO). A stock solution of MβCD 344 
was prepared in DMEM. Where appropriate, an equivalent dilution of DMSO was 345 
included as the control treatment.  346 
 347 
Quantification of virus infection assays  348 
To quantify MNV-1 infection, a modification of an enzyme-linked immunospot 349 
(ELISPOT) assay was used (Berryman et al., 2005). Briefly, 3x104 cells were seeded per 350 
well in 96-well tissue culture plates and grown overnight until approximately 80% 351 
confluent. The cells were incubated for 1 h at 37°C with MNV-1 at a multiplicity of 352 
infection (MOI) of ~2 pfu/cell. The cells were washed to remove excess virus and 353 
incubated in growth media at 37°C for a further 11 h. Cells were fixed by the addition of 354 
cold 4% paraformaldehyde (PFA; Sigma) in phosphate-buffered saline (PBS) for 1 h. The 355 
cells were then permeabilized with 0.1% Triton X-100 in PBS for 15 min. Following 356 
incubation for 0.5 h in blocking buffer (0.5% BSA in PBS), the cells were incubated with 357 
anti-MNV NS7 polymerase antisera (1:1500) for 1 h at RT. The cells were washed again 358 
and incubated with a biotinylated goat anti-rabbit IgG antisera (1:400; Southern 359 
Biotechnologies) followed by a streptavidin-conjugated alkaline phosphatase (1:1000; 360 
Caltag Laboratories) in blocking buffer for 1 h at RT. The alkaline phosphatase substrate 361 
(Bio-Rad) was added for 10 min, according to the manufacturer’s instructions. The 362 
infected cells stained dark blue and were quantified using an ELISPOT plate reader 363 
(Zeiss KS ELIspot). Nonspecific labelling was determined by performing the assay on 364 
mock-infected cells. 365 
To determine the effect of pharmacological inhibitors of endocytosis on MNV-1 366 
infection, cells were (i) pre-treated with the drug for 0.5 h prior to infection with MNV-1 367 
for 1h, also in the presence of the drug; or (ii) treated with the drug for 1.5 h immediately 368 
after the virus inoculum was removed, or (iii) the drug was added 1.5 h after the virus 369 
inoculum was removed. In the case of the dynasore, the drug was present throughout the 370 
assay.   371 
To control for effects of the inhibitors on virus in solution, virus was incubated 372 
with 7.5 mM of MβCD or 50 µM dynasore for 15 mins at RT.  Control virus was 373 
incubated with DMSO alone. Drug treated and control viruses were then titrated by 374 
TCID50 assay as described previously (Bailey et al, 2008). 375 
Following MβCD treatment, cells were treated with 400 µg/ml water soluble 376 
cholesterol for 15 mins at RT, before removing the medium, to replete the cholesterol in 377 
the plasma membrane.  Cells were subsequently infected with MNV-1 as described above 378 
and virus infection quantified by confocal microscopy.  379 
 380 
Transfections 381 
Transient transfection of RAW264.7 cells with plasmids expressing dominant 382 
negative or control Eps15 (gift from Alexandre Benmerah, Université Paris Descartes, 383 
Paris, France) was performed using Fugene HD (Roche) and 2 µg DNA per well (24 well 384 
plate), according to the manufacturer’s instructions. siRNAs targeted against flotillin-1 385 
(5’ GCUACACUUUGAAGGAUAU) or adaptin-2 (AP-2; 5’ 386 
GACCCACAUUGAUACAGUU; Eurogentec) were transfected into RAW264.7 cells as 387 
follows; cells (3x104) were seeded on 13-mm glass coverslips (BDH) and 0.1 µM of the 388 
siRNA, or a control siRNA duplex targeted against GFP, was added per well. Forty-eight 389 
hours post-transfection, the cells were infected with MNV-1 (MOI ~ 2) for 1 h at 37oC. 390 
Excess virus was removed and the cells incubated for a further 11 h. The cells were 391 
washed with PBS, fixed with cold 4% PFA for 1 h and processed for confocal 392 
microscopy using the anti-MNV NS7 polymerase antisera (1:1500) as described below. 393 
To confirm siRNA-mediated knockdown of the targeted proteins, cell extracts were 394 
subjected to SDS-PAGE and immunoblotting using anti-flotillin-1 and anti-AP-2 antisera. 395 
Membranes were re-probed with anti-GAPDH antisera as a loading control. 396 
 397 
Immunofluorescence confocal microscopy 398 
RAW264.7 cells (3 x 104cells/well) were seeded onto 13-mm glass coverslips 399 
(BDH) and infected with MNV-1 in the presence/absence of endocytosis inhibitors, as 400 
described above. Cells were washed with PBS, fixed with cold 4% PFA for 1 h, and 401 
permeabilized for 15 min with 0.1% Triton X-100 in blocking buffer. The cells were 402 
incubated with primary antibody for 1 h at RT, washed and incubated with the 403 
appropriate Alexa-conjugated secondary antibody in blocking buffer for 1 h at RT. After 404 
washing, the cells were incubated with TO-PRO-3 iodide (Invitrogen) for 10 min at RT to 405 
stain the cell nuclei. The cells were mounted onto slides using Vectashield mounting 406 
medium (Vector Labs) and sealed. Uptake of Alexa-labelled ligands (Dextran 0.5µg/ml, 407 
Cholera toxin B 10µg/ml and Transferrin 15 µg/ml) was carried out for the times 408 
indicated in the figures before fixing the cells and processing for microscopy as described 409 
above. If labelling with antibodies was not required, cells were processed without 410 
permeabilization. Microscopy was performed using a ZEISS 510Meta, equipped with a 411 
63x 1.4 NA Zeiss apochomat objective. All data were collected sequentially, to eliminate 412 
cross talk between the fluorescent dyes, using the same microscope settings.  413 
 414 
Immunoblotting   415 
Cell pellets were resuspended in RIPA buffer (50mM Tris-cl pH 7.4,150mM 416 
NaCl, 1% NP40, 0.25% Na-deoxycholate, 1mM PMSF) and centrifuged at 14,000 rpm 417 
for 5 min at 4 0C. Lysates were subjected to SDS-PAGE (12%) and proteins transferred 418 
to nitrocellulose membranes. Membranes were probed with the indicated primary 419 
antibodies followed by horseradish peroxidase (HRP)-conjugated species-specific 420 
secondary antibodies (1:2000; Dako). Proteins were visualised by chemiluminescence 421 
(Pierce).  422 
 423 
Statistical analysis  424 
All studies were performed independently at least three times.  The mean and 425 
standard error of the mean are shown.  GraphPad prism 5 (GraphPad) was used to 426 
perform the statistical analysis. One way Anova with Dunnett post-hoc test was used to 427 
evaluate the differences between treatments. Significance was determined by a P value of 428 
< 0.05, and significance is indicated in each figure. 429 
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Figure legends 435 
 436 
Figure 1: MNV-1 entry is clathrin-independent  437 
(A) RAW264.7 cells were transiently transfected to express control Eps15 (DIII∆2) or 438 
dominant negative Eps-15 (ED95/295 Eps15) as fusions with eGFP. Transfected cells 439 
were identified by eGFP expression. At 12 h post-transfection, cells were infected with 440 
MNV-1 (MOI ~2) for 12 h.  Infected cells were quantified by confocal microscopy using 441 
an antibody to the viral NS7 polymerase protein. Results are shown as the level of 442 
infection of the DN Eps15-expressing cells normalized to the level of infection of the 443 
cells expressing the control protein. The mean ±SE of 3 independent experiments is 444 
shown. (B) RAW264.7 cells were transfected to express the control or DN-Eps15 as 445 
described in panel A. At 12 h post-transfection, Alexa-568-conjugated transferrin (red) 446 
was internalized for 10 min and then chased for 20 min in the absence of transferrin. The 447 
nuclei were stained with TO-PRO-3 iodide and are shown in blue.  Scale bar 10 µm. (C) 448 
Transferrin internalization was quantified by confocal microscopy.  Results are shown as 449 
the level of transferrin uptake by the DN Eps15-expressing cells normalized to the level 450 
of uptake by the cells expressing the control protein. The mean ±SE of 3 independent 451 
experiments is shown. (D) RAW264.7 cells were transfected with siRNA targeted against 452 
AP-2 or a control siRNA against GFP. At 48 h post-transfection, Alexa-568-conjugated 453 
transferrin (red) was internalized for 10 min and then chased for 20 min in the absence of 454 
transferrin. The nuclei were stained with TO-PRO-3 iodide and are shown in blue.  Scale 455 
bar 10 µm. (E) RAW264.7 cells were transfected with siRNA targeted against AP-2 or 456 
siRNA against GFP and at 48 h post-transfection, cell lysates were analyzed by SDS-457 
PAGE and immunoblotting with AP-2 and GAPDH antisera. (F) 48 h post-transfection 458 
with the AP-2 and GFP siRNAs, cells were infected with MNV-1 (MOI ~ 2) for 12 h and 459 
infected cells quantified as above.  Results are shown as the level of infection of the AP2 460 
siRNA-transfected cells normalized to the level of infection of the cells transfected with 461 
the control GFP siRNA. The mean ±SE from 3 independent experiments is shown. (G) 462 
The siRNA-transfected cells were quantified for transferrin internalization by confocal 463 
microscopy. Results are shown as the level of transferrin uptake by the AP-2 siRNA 464 
transfected cells normalized to the level of uptake by the cells transfected with the control 465 
siRNA. The mean ±SE of 3 independent experiments is shown.  466 
 467 
Figure 2: MNV-1 entry is not pH-dependent 468 
(A) RAW264.7 cells were infected with MNV-1 (MOI  ~2), or mock-infected, for 1 h at 469 
37°C. The cells were washed and incubated in culture medium for a further 11 h and then 470 
fixed and permeabilized. Infected cells were quantified using the ELISPOT assay. Panel 471 
(i) shows a mock-infected cell monolayer. Panel (ii) shows an infected cell monolayer. 472 
(B) RAW264.7 cells were pre-treated with different concentrations of concanamycin A 473 
for 0.5 h prior to infection with MNV-1 (MOI ~ 2) for 1 h in the presence of the drug. 474 
Control-treated cells were treated with an equivalent dilution of DMSO. The cells were 475 
then washed and incubated in culture medium for a further 11 h, and infection quantified 476 
using the ELISPOT assay.  Results are shown as the level of infection of the drug treated 477 
cells normalized to the level of infection in the absence of the drug. The mean ±SE from 478 
3 independent experiments is shown. 479 
 480 
Figure 3: MNV-1 entry is cholesterol-dependent 481 
(A) RAW264.7 cells were pre-treated with different concentrations of MβCD prior to 482 
infection with MNV-1 (MOI ~ 2) for 1 h in the presence (or absence) of the drug. Virus 483 
and drug were removed and infection quantified at 12 h.p.i using the ELISPOT assay. To 484 
control for effects on intracellular virus replication, the drug was added for 1.5 h either 485 
immediately after the virus inoculum had been removed, or 1.5 h after the virus inoculum 486 
was removed. The results are shown as the level of infection of the drug-treated cells 487 
normalized to the level of infection in the absence of the drug The mean ±SE from 3 488 
independent experiments is shown. *p<0.05, **p<.0.01 (B) RAW264.7 cells were treated 489 
(or control treated) with 7.5 mM MβCD for 0.5 h, prior to the internalization of Alexa-490 
555-conjugated CTB (shown in green) for 0.5 h.  The nuclei were stained with TO-PRO-491 
3 iodide (blue). Scale bars = 10 µm. (C) For repletion of cholesterol following MβCD 492 
treatment, cells were treated with 400ug/ml water soluble cholesterol prior to infection, as 493 
above. Results shown are representative of two independent experiments. (D) RAW264.7 494 
cell and HEK293 cell lysates were subjected to SDS-PAGE and immunoblotting with 495 
anti-caveolin-1 and anti-GAPDH antisera.   496 
 497 
Figure 4: MNV-1 entry is dynamin-dependent and involves microtubules  498 
(A) RAW264.7 cells were treated with dynasore (or DMSO) for 0.5 h prior to infection 499 
with MNV-1 (MOI ~2) for 12h, with the drug remaining present throughout the assay. 500 
Infected cells were quantified by ELISPOT assay as described in Figure 2. To control for 501 
post-entry effects on virus replication, the drug was added immediately after, or 1.5 h 502 
after, the virus inoculum was removed. The results are shown as the level of infection of 503 
the drug-treated cells normalized to the level of infection in the absence of the drug. The 504 
mean ±SE from 3 independent experiments is shown. ***p<0.001. (B) RAW264.7 cells 505 
were pretreated with nocodazole (or DMSO) prior to infection with MNV-1 (MOI of ~2) 506 
for 12 h. Infection was quantified by ELIspot assay. The drug was also added post entry 507 
as described above. The results are shown as the level of infection of the drug-treated 508 
cells normalized to the level of infection in the absence of the drug.  Shown is the mean 509 
±SE from 3 experiments. *p<0.05, **p<, ***p<0.001.  510 
 511 
Figure 5: Role of macropinocytosis and F-actin in MNV-1 infection 512 
(A) RAW264.7 cells were pretreated with 25 µM and 50 µM EIPA prior to infection with 513 
MNV-1 (MOI of ~2) for 12 h. Infection was quantified by ELISPOT assay as described 514 
in Figure 2. The results are shown as the level of infection of the drug treated cells 515 
normalized to the level of infection of the mock treated cells.  Shown is the mean ±SE 516 
from 3 experiments. *p<0.05. (B) RAW264.7 cells were pretreated with 50 µM EIPA for 517 
0.5 h and incubated with 0.5 µg/ml Alexa-labelled dextran (red) for 0.5 h. The 518 
intracellular distribution of fluorescent dextran in EIPA-treated samples was compared to 519 
that in the untreated cells. The nuclei were stained with TO-PRO-3 iodide (blue). Scale 520 
bars = 10 µm. (C) RAW264.7 cells were pretreated with 2, 4 or 8 µM cytochalasin D 521 
prior to infection with MNV-1 (MOI of  ~2). Infection was quantified by ELISPOT.  522 
Shown is the mean ±SE from 3 experiments. (D) RAW264.7 cells were pretreated with 4 523 
µM cytochalasin D and the actin microfilaments stained with phalloidin. Nuclei were 524 
stained as described above. Scale bars = 10 µm.  525 
 526 
Figure 6: Flotillin-1 is not involved in MNV-1 infection 527 
RAW264.7 cells were transfected with siRNA targeted against flotillin-1 or GFP 528 
(control). (A) 48 h post-transfection, cell lysates were prepared and analyzed by 529 
immunoblotting with anti-flotillin-1 and anti-GAPDH antisera. (B) 48 h post-transfection, 530 
cells were infected with MNV-1 (MOI ~ 2), virus inoculum was removed after 1h and the 531 
infection continued for a further 11 h.  The cells were fixed and permeabilized and 532 
infected cells detected using anti-MNV-1 NS7 polymerase antisera and an Alexa-543 533 
goat anti-rabbit IgG antibody before visualization by confocal microscopy. Results are 534 
shown as the level of infection of the flotillin-1 siRNA transfected cells (Flot-1) 535 
normalized to the level of infection of the cells transfected with the GFP siRNA. The 536 
mean ±SE from 3 independent experiments is shown.  537 
 538 
 539 
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